{"nct_id": "NCT00264966", "eligibility_text": "Inclusion Criteria:. * Part 1: Men and women 18 to 65 years of age; generally good health; mild to moderate, stable, allergic asthma as defined by ATS criteria (1); history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline ≥70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.. Part 2: Methacholine challenge at baseline (PC20 ≤16 mg/mL); positive skin-prick test to common aeroallergens (cat, dust mite, grass, pollen) and positive allergen-induced early and late airway bronchoconstriction.. Exclusion Criteria:. * Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting β2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Part 1: Men and women 18 to 65 years of age"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 65, "unit": "years", "evidence_text": "* Part 1: Men and women 18 to 65 years of age"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "pregnant or lactating women"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "women actively seeking pregnancy or who are not using adequate contraception"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Part 1: Men and women 18 to 65 years of age"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "* Part 1: Men and women 18 to 65 years of age"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "asm8", "unit": null, "evidence_text": "use of medications that may interact with ASM8"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "baseline saline in methacholine challenge during screening", "unit": null, "evidence_text": "20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "episodic wheeze and shortness of breath", "unit": null, "evidence_text": "history of episodic wheeze and shortness of breath"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 28, "unit": "days", "evidence_text": "use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting β2-agonist are allowed)"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "pregnant or lactating women"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "breastfeeding", "unit": null, "evidence_text": "pregnant or lactating women"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "women actively seeking pregnancy or who are not using adequate contraception"}]}
{"nct_id": "NCT00269867", "eligibility_text": "Inclusion Criteria:. * Patients with active Rheumatoid Arthritis despite treatment with methotrexate. * Diagnosed with Rheumatoid Arthritis at least 6 months prior to screening. * Having active disease at the time of screening and pre-infusion as defined by having at least 6 or more swollen joints and 6 or more tender joints. * Using methotrexate for at least 3 months prior to study enrollment. Exclusion Criteria:. * Patients having any systemic inflammatory condition. * Having Lyme disease or a rheumatic disease other than Rheumatoid Arthritis. * Who have used Disease-Modifying Antirheumatic Drugs (DMARDs) other than methotrexate within 4 weeks prior to screening. * Who have used corticosteroids within 4 weeks prior to screening. * Having received previous administration of infliximab", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "* Using methotrexate for at least 3 months prior to study enrollment"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 6, "unit": "years", "evidence_text": "* Diagnosed with Rheumatoid Arthritis at least 6 months prior to screening"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 6, "unit": "years", "evidence_text": "* Having active disease at the time of screening and pre-infusion as defined by having at least 6 or more swollen joints and 6 or more tender joints"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "rheumatoid arthritis at least 6 months prior", "unit": null, "evidence_text": "* Diagnosed with Rheumatoid Arthritis at least 6 months prior to screening"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "active rheumatoid arthritis despite treatment with methotrexate", "unit": null, "evidence_text": "* Patients with active Rheumatoid Arthritis despite treatment with methotrexate"}]}
{"nct_id": "NCT00270907", "eligibility_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months.", "labeled_rules": [{"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 6, "unit": "years", "evidence_text": "Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 18, "unit": "years", "evidence_text": "There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 24, "unit": "years", "evidence_text": "Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "central nervous system metastases", "unit": null, "evidence_text": "History of central nervous system metastases"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "stem cell transplantation", "unit": null, "evidence_text": "Previous history of stem cell transplantation"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "typical paclitaxel- or docetaxel-induced grade 1-2 hypersensitivity", "unit": null, "evidence_text": "History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "exceptions to this would include", "unit": null, "evidence_text": "Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "requirements", "unit": null, "evidence_text": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "while there is no strict exclusion based", "unit": null, "evidence_text": "While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "institutional policy", "unit": null, "evidence_text": "Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "creatinine levels above institutional normal", "unit": null, "evidence_text": "creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "within normal limits unless", "unit": null, "evidence_text": "coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.)"}]}
{"nct_id": "NCT00289627", "eligibility_text": "Inclusion Criteria:. * Patients with previously treated Stage III (unresectable)or Stage IV melanoma", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* Patients with previously treated Stage III (unresectable)or Stage IV melanoma"}]}
{"nct_id": "NCT00289822", "eligibility_text": "Inclusion Criteria:. * Patients aged 18 to 80. * Patients post-myocardial infarction (\\> 3 months old) or with diffuse ischemic CHD. * Signed informed consent. Exclusion Criteria:. \\- Existing neoplastic disease or signs of tumor recurrence within the last 5 years. * Active infection. * Active internal bleeding. * Stroke within the past 2 years. * Surgery or trauma within the past two months. * Uncontrolled hypertension over 160/100. * Arteriovenous malformations or aneurysms. * HIV infection. * Signs of significant kidney or liver failure (creatinine \\> 2.0 mg/dL, GOT \\> 2 x upper standard value). * Thrombopenia (\\< 100,000). * Anemia (hemoglobin \\< 8.5 g/dL). * Mental retardation. * Participation in another clinical study. * Women of childbearing age. * Chronic inflammatory disease", "labeled_rules": [{"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 160, "unit": "years", "evidence_text": "* Uncontrolled hypertension over 160/100"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women of childbearing age"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "* HIV infection"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* Active infection"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "diffuse ischemic chd", "unit": null, "evidence_text": "* Patients post-myocardial infarction (\\> 3 months old) or with diffuse ischemic CHD"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 5, "unit": "years", "evidence_text": "\\- Existing neoplastic disease or signs of tumor recurrence within the last 5 years"}]}
{"nct_id": "NCT00291577", "eligibility_text": "Inclusion Criteria:. * Breast cancer with evidence of unresectable, locally recurrent or metastatic disease. * Candidate for treatment with docetaxel. Exclusion Criteria:. * Prior chemotherapy in the advanced disease setting. * Inflammatory breast cancer. * HER2 positive disease", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "docetaxel", "unit": null, "evidence_text": "* Candidate for treatment with docetaxel"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "evidence of unresectable, locally recurrent or metastatic", "unit": null, "evidence_text": "* Breast cancer with evidence of unresectable, locally recurrent or metastatic disease"}]}
{"nct_id": "NCT00292175", "eligibility_text": "Inclusion Criteria:. * petients with colitis who meet surveillance criteria. * patients over 18 years of age. Exclusion Criteria:. * pregnant patients. * unable or unwilling to give informed consent. * patients with severe active colitis who would be unsafe to endoscope", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* patients over 18 years of age"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "pregnant", "unit": null, "evidence_text": "* pregnant patients"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "severe active colitis who would be unsafe", "unit": null, "evidence_text": "* patients with severe active colitis who would be unsafe to endoscope"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "colitis who meet surveillance", "unit": null, "evidence_text": "* petients with colitis who meet surveillance criteria"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* pregnant patients"}]}
{"nct_id": "NCT00320034", "eligibility_text": "Inclusion Criteria:. * Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contraception) subjects age 18-55.. * Stable, mild atopic asthma with forced expiratory volume in one second (FEV1.0) greater than 70% of predicted for age and height, and not requiring any medical treatment other than short acting inhaled beta-agonists as needed.. * No recent or significant history of cigarette smoking (no cigarettes within six months prior to entry into the study; less than 10 pack-years cumulative history of cigarette smoking).. * Peak decrease in FEV1 in both early (0-2 hour) and late (3-7 hour) allergen-provoked response of \\> 15% compared with the baseline (pre-allergen challenge) spirometric determination.. * Signed written informed consent to participate in the protocol; ability to return to the outpatient clinic for repeated clinic visits.. * No history of asthma exacerbations or acute intercurrent respiratory illness (viral respiratory syndrome, bronchitis, pneumonia) for a six week period preceding entry into the screening phase of the study.. Exclusion Criteria:. * Significant gastrointestinal (including hepatic), hematological, cardiovascular, cerebrovascular or other body system disorder.. * History of an acute exacerbation, or of a respiratory tract infection at any time during the past 6 weeks.. * Baseline AST or ALT (indicators of liver damage) greater than twice the upper limit of the normal range for the local laboratory.. * History of allergy or hypersensitivity to short-acting beta-agonists.. * Inability to discontinue asthma medications for the duration of the study or receipt of oral or inhaled corticosteroids or leukotriene receptor antagonist in the three weeks prior to entry into the screening phase of the study.. * Recent (within the past 2 months) or planned (within the study period) lung volume reduction surgery.. * Psychosis, alcoholism, active substance abuse, or any personality disorder which would make compliance with this protocol problematic.. * Pregnant or nursing females.. * Any other medical or social condition which, in the opinion of the investigator, could confound the interpretation of the data derived from this study.", "labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contraception) subjects age 18-55"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergy or hypersensitivity to short-acting beta-agonists", "unit": null, "evidence_text": "* History of allergy or hypersensitivity to short-acting beta-agonists"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "this protocol problematic", "unit": null, "evidence_text": "* Psychosis, alcoholism, active substance abuse, or any personality disorder which would make compliance with this protocol problematic"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Pregnant or nursing females"}]}
{"nct_id": "NCT00322517", "eligibility_text": "Inclusion Criteria:. * Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent.. * Must have received prior treatment with an anthracycline and a taxane either concurrently or sequentially in the adjuvant and/or advanced disease treatment settings. Patients may have received as many as 2 other chemotherapy regimens in the advanced disease setting. Patients whose tumors are Her-2-positive must have received prior trastuzumab therapy. Prior hormonal therapy or immunotherapy in the adjuvant and/or advanced/metastatic disease settings is permitted. Prior treatment with surgery, radiotherapy, chemoembolization therapy, or cryotherapy is allowed if these therapies did not affect the areas of measurable disease.. Exclusion Criteria:. * Prior treatment with \\>/= 3 regimens of chemotherapy in the metastatic disease setting beyond those containing anthracyclines and taxanes. * Uncontrolled brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients should have completed surgery or radiation therapy for existing brain metastases, should not have documented increase in size over the previous 3 months and should be asymptomatic", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "curative intent", "unit": null, "evidence_text": "* Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent"}]}
{"nct_id": "NCT00329732", "eligibility_text": "Inclusion Criteria:. * Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine. * Presenting to clinic in migraine status, meaning the migraine has continued for greater than or equal to 3 days but less than 3 months.. * Pain must be reported as at least moderate pain level at time of injections. Exclusion Criteria:. A subject is ineligible to participate in this study if he/she satisfies any of the following criteria:. * Subjects who have received greater occipital nerve blocks in the past. * Subjects who in their own or the investigator's opinion are unable to describe their symptoms. * Subjects who are pregnant or lactating", "labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a previous diagnosis fulfilling ihs for episodic", "unit": null, "evidence_text": "* Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Subjects who are pregnant or lactating"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "breastfeeding", "unit": null, "evidence_text": "* Subjects who are pregnant or lactating"}]}
{"nct_id": "NCT00339703", "eligibility_text": "Inclusion Criteria:. * Inclusion criteria for the asthmatic group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age, (c) asthma defined as moderate or severe persistent by NHLBI guidelines, and characterized by at least daily symptoms, night symptoms at least once weekly, and a FEV1 between 60-80% of predicted. Newly diagnosed asthmatics, poorly controlled asthmatics, and hospitalized patients with asthma flares may also be considered in separate arms of this study.. * Inclusion criteria for the control group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age.. Exclusion Criteria:. * Exlusion criteria for the asthmatic group will consist of the following: (a) current use of oral steroids or statins, (b) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation.. * Exclusion criteria for the control group will consist of the following: (a) current use of oral steroids or statins, (b) prior diagnosis of asthma, or clinical symptoms consistent with asthma or reactive airway disease, (c) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Inclusion criteria for the control group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 65, "unit": "years", "evidence_text": "* Inclusion criteria for the control group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Inclusion criteria for the asthmatic group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age, (c) asthma defined as moderate or severe persistent by NHLBI guidelines, and characterized by at least daily symptoms, night symptoms at least once weekly, and a FEV1 between 60-80% of predicted"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 65, "unit": "years", "evidence_text": "* Inclusion criteria for the asthmatic group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age, (c) asthma defined as moderate or severe persistent by NHLBI guidelines, and characterized by at least daily symptoms, night symptoms at least once weekly, and a FEV1 between 60-80% of predicted"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Inclusion criteria for the control group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Inclusion criteria for the asthmatic group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age, (c) asthma defined as moderate or severe persistent by NHLBI guidelines, and characterized by at least daily symptoms, night symptoms at least once weekly, and a FEV1 between 60-80% of predicted"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "asthma flares may also be considered in", "unit": null, "evidence_text": "Newly diagnosed asthmatics, poorly controlled asthmatics, and hospitalized patients with asthma flares may also be considered in separate arms of this study"}]}
{"nct_id": "NCT00345748", "eligibility_text": "Inclusion Criteria:. * patients with active Rheumatoid Arthritis while on methotrexate having 12 tender and 10 swollen joints at randomization. Exclusion Criteria:. * no current infection or other evolutive or uncontrolled disease", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* patients with active Rheumatoid Arthritis while on methotrexate having 12 tender and 10 swollen joints at randomization"}]}
{"nct_id": "NCT00349427", "eligibility_text": "Inclusion:. * Patients with type 2 Diabetes mellitus on a minimum dose of 30 units/day insulin monotherapy continuously for at least 8 weeks. * If Patients are taking another oral antidiabetic agent may stop their oral agent and adjust their insulin dose properly over 8 weeks prior to screening if they are asked by doctor who considers him/her suitable for study in all other respects, and the HbA1c level\\>7.5%.. Exclusion:. * Fasting plasma glucose \\>13 mmol/L at screening. * Ongoing edema or history of peripheral edema requiring pharmacological treatment within 12 months. * Drug abuse. * Women pregnant or lactating. * Use any rosiglitazone like drug in 3 months. * Use more than one oral antidiabetic agent in 2 months. * Uncontrolled hypertension. * Chronic heart failure. * Anemia", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 8, "unit": "years", "evidence_text": "* Patients with type 2 Diabetes mellitus on a minimum dose of 30 units/day insulin monotherapy continuously for at least 8 weeks"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 8, "unit": "years", "evidence_text": "* If Patients are taking another oral antidiabetic agent may stop their oral agent and adjust their insulin dose properly over 8 weeks prior to screening if they are asked by doctor who considers him/her suitable for study in all other respects, and the HbA1c level\\>7.5%"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women pregnant or lactating"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "peripheral edema requiring pharmacological treatment within 12", "unit": null, "evidence_text": "* Ongoing edema or history of peripheral edema requiring pharmacological treatment within 12 months"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Women pregnant or lactating"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "breastfeeding", "unit": null, "evidence_text": "* Women pregnant or lactating"}]}
{"nct_id": "NCT00351988", "eligibility_text": "Inclusion Criteria:. 1. Caregiver inclusion criteria includes: provides care and/or assistance to a patient receiving new or current treatment - Single or combined chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and other).. 2. 18 years of age or older;. 3. self-identified as African-American/Black, Latino, or white, non-Latino;. 4. able to speak English or Spanish (as applicable);. 5. able to read and complete forms or be willing to have the forms read to them by a trained interviewer;. 6. accessible through personal or telephone contact for the duration of the study.. 7. Patient inclusion criteria: Receiving new or current treatment - Single or combined - chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and others). Criteria 2-6 are the same as listed under Caregiver Criteria.. Exclusion Criteria: None", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "1"}]}
{"nct_id": "NCT00356629", "eligibility_text": "Inclusion criteria. * Subjects suffering from CF, COPD, asthma and tobacco exposure (groups 1 to 4) and controls (group 5). * aged more or equal to 18. * stable disease. * able to perform PFTs. * informed consent signed. * affiliated to french social insurance. Exclusion Criteria:. * acute exacerbation of the disease during the last 2 weeks. * IV or oral steroids or antibiotics during the last 2 weeks. * hospitalization during the last 2 weeks. * colonization by S aureus methicillin resistant and/or Burkholderia cepacia", "labeled_rules": [{"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 2, "unit": "weeks", "evidence_text": "* hospitalization during the last 2 weeks"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 2, "unit": "weeks", "evidence_text": "* acute exacerbation of the disease during the last 2 weeks"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 2, "unit": "weeks", "evidence_text": "* IV or oral steroids or antibiotics during the last 2 weeks"}]}
{"nct_id": "NCT00369499", "eligibility_text": "Inclusion Criteria:. * Migraine history of at least 1 year.. * Migraine patients experiencing at least 2 migraine attacks per month.. * Migraine patients experiencing at least 1 migraine attack with aura per month.. * Failure of or intolerance to at least 2 classes of prophylactic migraine medication evaluated in adequate, approved medication trials. At least one of the classes shall come from beta-blockers, anticonvulsants, calcium channel blockers and tricyclic antidepressants.. * Aged 18 - 50 years and of legal age in the host country.. * The patient or legal guardian has signed a study specific informed consent form agreeing to data collection and follow-up requirements.. * The patient agrees to abstain from starting prophylactic migraine medication or agrees to maintain existing prophylactic migraine medication without changing dose or drug from entering the baseline period throughout the duration of the study until final assessments.. * Documented right to left shunt that is suitable for device closure.. Exclusion Criteria:. * Taking migraine preventative medication for conditions other than migraine.. * History of 15 or more headache days per month.. * 8 or more non-migraine headache days per month.. * Overuse of acute headache medication (use on 10 or more days per month).. * Patient has severe central nervous system disease such as seizure disorder, inflammatory disease of the central nervous system, or a previous stroke.. * Previous surgical or device closure of a PFO or ASD.. * Artificial heart valve.. * Pacemaker or ICD implanted within past 3 months.. * Anatomic variant that could affect successful deployment such as coronary sinus, pulmonary veins, Chiari network.. * Uncontrolled bacteremias or dental or surgical procedure within past 30 days or planned within study period.. * Allergy to contrast media, and/or to any component of the device to be used.. * Contraindicated for any medication used during or after the procedure.. * History of atrial fibrillation or atrial flutter (chronic or paroxysmal).. * Patient is enrolled or intends to participate in another clinical study (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during the study or within four weeks prior to his/her enrollment in the study.. * Patient is undergoing dialysis for renal failure.. * Patient has NYHA class 3 or 4 cardiac failure.. * Patient is pregnant, or intends to become pregnant during the trial period.. * Patient requires anticoagulation therapy for a concomitant condition.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* Migraine history of at least 1 year"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Aged 18 - 50 years and of legal age in the host country"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 50, "unit": "years", "evidence_text": "* Aged 18 - 50 years and of legal age in the host country"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 2, "unit": "years", "evidence_text": "* Migraine patients experiencing at least 2 migraine attacks per month"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* Migraine patients experiencing at least 1 migraine attack with aura per month"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 2, "unit": "years", "evidence_text": "* Failure of or intolerance to at least 2 classes of prophylactic migraine medication evaluated in adequate, approved medication trials"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "at least 1 year", "unit": null, "evidence_text": "* Migraine history of at least 1 year"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "migraine", "unit": null, "evidence_text": "* Migraine patients experiencing at least 2 migraine attacks per month"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "aura per month", "unit": null, "evidence_text": "* Migraine patients experiencing at least 1 migraine attack with aura per month"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Patient is pregnant, or intends to become pregnant during the trial period"}]}
{"nct_id": "NCT00383968", "eligibility_text": "Inclusion criteria:. * Known hypertensives aged 40 and above with microalbuminuria and/or elevated serum creatinine on first evaluation.. * Hypertension: Systolic blood pressure ≥140, and /or diastolic blood pressure ≥ 90 with or without antihypertensive drugs.. * Microalbuminuria:. * Albumin concentration of 20-200mg/L, with albumin-to-creatinine ratio of 3-30mg/mmol or 30-300mg/g. * Female: 3.0-30.0mg/mmol or 30-300mg/g. * Male: 2.0-20.0mg/mmol or 20. * Elevated Serum creatinine:. * Female: \\>1.2mg/dl. * Male: \\>1.4mg/dl. Exclusion Criteria:. * Known diabetics will be excluded.. * unable to give informed consent", "labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "* Male: \\>1.4mg/dl"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female: \\>1.2mg/dl"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "* Male: 2.0-20.0mg/mmol or 20"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female: 3.0-30.0mg/mmol or 30-300mg/g"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "or without antihypertensive drugs", "unit": null, "evidence_text": "* Hypertension: Systolic blood pressure ≥140, and /or diastolic blood pressure ≥ 90 with or without antihypertensive drugs"}]}
{"nct_id": "NCT00384722", "eligibility_text": "Inclusion Criteria:. * Must be indicated for a Guidant CRT-P or CRT-D device. * Creatinine \\< 2.5 mg/dL obtained no more than two weeks prior to enrollment. * Age 18 or above, or of legal age to give informed consent specific to state and national law. * Willing and capable of providing informed consent, undergoing a device implant, participating in all testing associated with this clinical investigation at an approved clinical investigation center and at the intervals defined by this protocol. * Geographically stable residents who are available for follow-up. Exclusion Criteria:. * Have a known hypersensitivity to a 0.5 mg nominal dose of dexamethasone acetate. * Have or had previous cardiac resynchronization therapy, a coronary venous pace/sense lead or attempted LV lead placement. * Have pre-existing cardioversion/defibrillation leads or right ventricular pacing leads other than those specified in the investigational plan (unless the investigator intends to replace them with permitted cardioversion/defibrillation leads). * Currently requiring dialysis. * Have had a myocardial infarct, unstable angina, percutaneous coronary intervention, or coronary artery bypass graft during the preceding 30 days prior to enrollment. * Have hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g., amyloidosis, sarcoidosis). * Documented life expectancy of less than six months or expected to undergo heart transplant within the next six months. * Enrolled or participating in any concurrent study, including drug investigations, without Guidant written approval, that may confound the results of this study. * Have a pre-existing unipolar pacemaker that will not be explanted/abandoned. * Have a mechanical tricuspid heart valve. * Women who are pregnant or plan to become pregnant. Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment.", "labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women who are pregnant or plan to become pregnant"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Women who are pregnant or plan to become pregnant"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment"}]}
{"nct_id": "NCT00398645", "eligibility_text": "Inclusion criteria:. * Type of Subject: Outpatient. * Age: 12 years of age or older at Visit 1 (or ³18 years of age or older if local regulations or the regulatory status of study medication permit enrollment of adults only).. * Gender: Male or eligible female - Females are eligible to participate only if they are currently non-pregnant and non-lactating. To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control, as defined by the following: Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject, Implants of levonorgestrel, Injectable progestogen, Oral contraceptive (either combined estrogen/progestin or progestin only), Any intrauterine device (IUD) with a documented failure rate of less than 1% per year, Double-barrier method - spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a spermicide and female diaphragm), The contraceptive transdermal patch, Ortho Evra (if the subject is less than 198 pounds), Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse throughout the clinical trial, and for a period after the trial to account for elimination of the drug (minimum of six days),. * Asthma Diagnosis: Asthma as defined by the National Institutes of Health \\[National Institutes of Health, 2002; GINA, 2005\\].. * Severity of Disease: A best AM FEV1 of 50% to 80% of the predicted value during Visit 1 based on the Standardization of Lung Function Tests \\[European Respiratory Society, 1993\\] standards for 18 years and older or Polgar \\[Polgar, 1971\\] standards for 12 to 17 years and race adjusted for African-Americans \\[American Thoracic Society, 1991\\].. * Reversibility of Disease: Demonstrated ³12% and 200mL reversibility of FEV1 within 30 minutes following 200 to 400mcg of albuterol/salbutamol inhalation aerosol (or one nebulized albuterol/salbutamol treatment) at Visit 1. If a subject fails to demonstrate an increase in FEV1 of ³12% and 200mL, the subject is not eligible for the study and will not be allowed to re-screen.. * Concurrent Anti-Asthma Therapy: Subjects must be using an inhaled corticosteroid for at least 3 months prior to Visit 1 and be maintained on a stable dose for four weeks prior to Visit 1 at one of the following doses: Anti-Asthma Therapy Maximum Daily Dose (mcg/day) Fluticasone propionate MDI CFC/HFA ≤220mcg1/≥250mcg2 Fluticasone propionate DPI 200mcg Beclomethasone dipropionate 420mcg1/500mcg2 Beclomethasone dipropionate HFA 160mcg1/200mcg2 Budesonide DPI 400mcg Flunisolide 1000mcg Triamcinolone acetonide 1000mcg Mometasone furoate 200mcg Ciclesonide 160mcg1/200mcg2. 1. Ex-actuator dose: dose delivered to the lungs. 2. Ex-valve dose: dose expressed from the valve. * Short-Acting Beta2-Agonist: All subjects must be able to replace short-acting beta2-agonists with albuterol/salbutamol inhalation aerosol at Visit 1 for use as-needed for the duration of the study. Subjects must be able to withhold all inhaled short-acting beta-sympathomimetic bronchodilators for at least 6 hours prior to study visits.Note: Nebulized albuterol/salbutamol will not be allowed during the study with the exception of its use during reversibility testing at Visit 1. The use of albuterol/salbutamol through the DISKUS/ACCUHALER device will not be allowed during the study.. * Informed Consent: All subjects must be able and willing to give written informed consent to take part in the study.. * Compliance: Subjects must be able to comply with all the study requirements.. Exclusion criteria:. * History of Life-Threatening Asthma: History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures.. * Anti-Asthma Medications: Asthma medications listed below must not have been used prior to Visit 1 for the required interval listed below, and not taken during the study: Within 24 hours of Visit 1: Oral short-acting beta2-agonists: Within 2 weeks of Visit 1:Combination therapy containing inhaled beta2-agonists and ICS for asthma (e.g., fluticasone propionate/salmeterol combination, budesonide/formoterol combination);Slow-release bronchodilators (e.g., aminophylline, theophylline);Anticholinergics; Long-acting beta2-agonists (e.g., salmeterol); Ketotifen; Nedocromil sodium; Sodium cromoglycate; Oral long-acting beta2-agonists. Within 4 weeks of Visit 1: Anti-leukotrienes including suppressors of leukotriene production and antagonists. Within 12 weeks of Visit 1: Systemic, oral, parenteral, or depot corticosteroids; Anti-IgE (e.g., omalizumab).. * Other Medications: The medications listed below must not have been used prior to Visit 1 for the required interval indicated below, and not taken during the study: Within 4 weeks of Visit 1: Known potent inhibitors of CYP3A4 (e.g., ritonavir, ketoconazole). * Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1. In addition, the subject must be excluded, if such infection occurs between Visits 1 and 2.. * Asthma Exacerbation: History of a an asthma exacerbation within 4 weeks of Visit 1, any asthma exacerbation requiring oral corticosteroids within 3 months of Visit 1, or any hospitalization due to asthma exacerbation within 6 months of Visit 1.. * Investigational Medications: A subject must not have used any investigational drug within 30 days prior to Visit 1 or within ten half-lives (t1/2) of the prior investigational study (which ever is longer of the two) or concurrently during the study.. * Concurrent Diseases/Abnormalities: Historical or current evidence of clinically significant uncontrolled disease including, but not limited to: cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, or pulmonary disease (including, but not confined to chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, bronchopulmonary dysplasia, and chronic obstructive pulmonary disease). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.. * Oropharyngeal Examination: A subject will not be eligible for the run-in if he/she has evidence of oropharyngeal candidiasis at Visit 1.. * Drug Allergy: Any adverse reaction including immediate or delayed hypersensitivity to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy.. * Milk Protein Allergy: History of severe milk protein allergy.. * Immunosuppressive Medications: A subject must not be using, or require use of, immunosuppressive medications during the study.. Note: Immunotherapy for the treatment of allergies is allowed during the study provided that it was initiated prior to Visit 1 and the subject is maintained on a stable daily dose throughout the study period.. * Attendance: A subject will not be eligible if he/she or his/her parent or legal guardian has any infirmity, disability, or geographical location which seems likely (in the opinion of the Investigator) to impair compliance with any aspect of this study protocol or scheduled visits to the study center and compliance with study medication or procedures (e.g., completion of daily diary). Neurological or psychiatric disease or history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol requirements excludes study participation.. * Tobacco Use: A subject may not have used tobacco products within the past one year (i.e., cigarettes, cigars, or pipe tobacco) and must not have historical use of \\>10 pack years (e.g., 20 cigarettes/day for 10 years).. * Affiliation with Investigator's Site: A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 6, "unit": "years", "evidence_text": "Subjects must be able to withhold all inhaled short-acting beta-sympathomimetic bronchodilators for at least 6 hours prior to study visits.Note: Nebulized albuterol/salbutamol will not be allowed during the study with the exception of its use during reversibility testing at Visit 1"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 12, "unit": "years", "evidence_text": "* Severity of Disease: A best AM FEV1 of 50% to 80% of the predicted value during Visit 1 based on the Standardization of Lung Function Tests \\[European Respiratory Society, 1993\\] standards for 18 years and older or Polgar \\[Polgar, 1971\\] standards for 12 to 17 years and race adjusted for African-Americans \\[American Thoracic Society, 1991\\]"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 17, "unit": "years", "evidence_text": "* Severity of Disease: A best AM FEV1 of 50% to 80% of the predicted value during Visit 1 based on the Standardization of Lung Function Tests \\[European Respiratory Society, 1993\\] standards for 18 years and older or Polgar \\[Polgar, 1971\\] standards for 12 to 17 years and race adjusted for African-Americans \\[American Thoracic Society, 1991\\]"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Severity of Disease: A best AM FEV1 of 50% to 80% of the predicted value during Visit 1 based on the Standardization of Lung Function Tests \\[European Respiratory Society, 1993\\] standards for 18 years and older or Polgar \\[Polgar, 1971\\] standards for 12 to 17 years and race adjusted for African-Americans \\[American Thoracic Society, 1991\\]"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "* Concurrent Anti-Asthma Therapy: Subjects must be using an inhaled corticosteroid for at least 3 months prior to Visit 1 and be maintained on a stable dose for four weeks prior to Visit 1 at one of the following doses: Anti-Asthma Therapy Maximum Daily Dose (mcg/day) Fluticasone propionate MDI CFC/HFA ≤220mcg1/≥250mcg2 Fluticasone propionate DPI 200mcg Beclomethasone dipropionate 420mcg1/500mcg2 Beclomethasone dipropionate HFA 160mcg1/200mcg2 Budesonide DPI 400mcg Flunisolide 1000mcg Triamcinolone acetonide 1000mcg Mometasone furoate 200mcg Ciclesonide 160mcg1/200mcg2"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Gender: Male or eligible female - Females are eligible to participate only if they are currently non-pregnant and non-lactating"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "A urine pregnancy test is required for all subjects at all visits, Female subjects should not be enrolled if they plan to become pregnant during the time of study participation"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control, as defined by the following: Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject, Implants of levonorgestrel, Injectable progestogen, Oral contraceptive (either combined estrogen/progestin or progestin only), Any intrauterine device (IUD) with a documented failure rate of less than 1% per year, Double-barrier method - spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a spermicide and female diaphragm), The contraceptive transdermal patch, Ortho Evra (if the subject is less than 198 pounds), Female subjects should not be enrolled if they plan to become pregnant during the time of study participation"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "severe milk protein allergy", "unit": null, "evidence_text": "* Milk Protein Allergy: History of severe milk protein allergy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a respiratory tract infection within 4 weeks", "unit": null, "evidence_text": "* Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypercapnia, respiratory arrest or hypoxic seizures", "unit": null, "evidence_text": "* History of Life-Threatening Asthma: History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "all the requirements", "unit": null, "evidence_text": "* Compliance: Subjects must be able to comply with all the study requirements"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the exception of its use during reversibility", "unit": null, "evidence_text": "Subjects must be able to withhold all inhaled short-acting beta-sympathomimetic bronchodilators for at least 6 hours prior to study visits.Note: Nebulized albuterol/salbutamol will not be allowed during the study with the exception of its use during reversibility testing at Visit 1"}]}
{"nct_id": "NCT00400491", "eligibility_text": "Inclusion Criteria:. * Type 2 diabetes for at least 1 year. * age 21-75 years. * long-acting insulin at bedtime. * metformin during the day. * for women of child bearing age use of reliable method of birth control. Exclusion Criteria:. * serum creatinine above 130 umol/l for men and above 110 for women. * systolic blood pressure \\> 175 or diastolic \\> 104 mmHg. * heart disease. * serum calcium \\> 2.54 mmol/l. * history of renal stones", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 21, "unit": "years", "evidence_text": "* age 21-75 years"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "* age 21-75 years"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* Type 2 diabetes for at least 1 year"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* serum creatinine above 130 umol/l for men and above 110 for women"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "* serum creatinine above 130 umol/l for men and above 110 for women"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* for women of child bearing age use of reliable method of birth control"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "renal stones", "unit": null, "evidence_text": "* history of renal stones"}]}
{"nct_id": "NCT00420290", "eligibility_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements ≥ 5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "patients with active infections (including chronic or local infection)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "pulmonary tb infection with or without documented", "unit": null, "evidence_text": "Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active tb, are excluded from the", "unit": null, "evidence_text": "Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C)"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "Pregnancy"}]}
{"nct_id": "NCT00421642", "eligibility_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent naïve or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 2, "unit": "years", "evidence_text": "Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Female subjects who are pregnant or breast-feeding"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "symptomatic obstructive strictures", "unit": null, "evidence_text": "Subjects with symptomatic obstructive strictures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "clinically significant drug or alcohol abuse in", "unit": null, "evidence_text": "History of clinically significant drug or alcohol abuse in the prior year"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "previously untreated tb", "unit": null, "evidence_text": "Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "uc for greater than 3 months", "unit": null, "evidence_text": "A diagnosis of UC for greater than 3 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "exclusion of infectious cause", "unit": null, "evidence_text": "UC diagnosis confirmed by endoscopy with exclusion of infectious cause"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the requirements of this protocol", "unit": null, "evidence_text": "Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "Female subjects who are pregnant or breast-feeding"}]}
{"nct_id": "NCT00422513", "eligibility_text": "Inclusion Criteria:. * adult patients, \\>=18 years of age;. * CKD (stage V) on outpatient hemodialysis therapy for \\>= 3 months;. * CKD-related anemia treated with epoetin alfa iv 3x/week for \\>= 3 months;. * average hemoglobin (Hb) 10-12 g/dL over last 3 months.. Exclusion Criteria:. * failed renal transplant within 12 months prior to screening;. * poorly controlled hypertension;. * previous treatment with Mircera.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "mircera", "unit": null, "evidence_text": "* previous treatment with Mircera"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "adult", "unit": null, "evidence_text": "* adult patients, \\>=18 years of age"}]}
{"nct_id": "NCT00437723", "eligibility_text": "Inclusion Criteria:. * adult patients,18-75 years of age;. * end-stage renal disease, not on dialysis;. * Hb \\<110g/L.. Exclusion Criteria:. * unstable hypertension;. * acute infections;. * use of i.v. NeoRecormon, or use of any other ESA beside NeoRecormon;. * myocardial infarction, unstable angina or venous thrombosis within 6 months before start of treatment.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* adult patients,18-75 years of age"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "* adult patients,18-75 years of age"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "adult", "unit": null, "evidence_text": "* adult patients,18-75 years of age"}]}
{"nct_id": "NCT00438984", "eligibility_text": "Inclusion Criteria:. * Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease. * Expression of HLA-A2, B44, or A3 as determined by Fred Hutchinson Cancer Research Center (FHCRC) human leukocyte antigen (HLA) typing lab. * Zubrod performance status of 0-1. * Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic imaging (X-ray, CT scan). * Normal cardiac stress test within 182 days prior to enrollment is required of all patients over 50 years old or those with an abnormal electrocardiogram (ECG), any history of cardiac disease, a family history of cardiac disease, hypercholesterolemia or hypertension. * FOR LEUKAPHERESIS:. * Pulse \\> 45 or \\< 120. * Weight \\>= 45 kg. * White blood cell count (WBC) \\>= 3,000. * Temperature =\\< 38C (=\\< 100.4 F). * Hematocrit (HCT) \\>= 30%. * Platelets \\>= 100,000. * FOR T CELL INFUSION: Patients must be willing and able to discontinue the use of all anti-hypertensive medications 24 hours prior to and during IL-2 therapy. Exclusion Criteria:. * Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to entry. * Serum creatinine \\> 1.6 mg/dL or Creatinine clearance \\< 75 ml/min. * Serum glutamic oxaloacetic transaminase (SGOT) \\> 150 IU or \\> 3x upper limit of normal. * Bilirubin \\> 1.6 mg/dL. * Prothrombin time \\> 1.5 x control. * Clinically significant pulmonary dysfunction, as determined by medical history and physical exam; patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in one second (FEV1) \\< 2.0 L or carbon monoxide diffusing capacity (DLco) (corr for Hgb) \\< 75% will be excluded. * Significant cardiovascular abnormalities as defined by any one of the following:. * Congestive heart failure;. * Clinically significant hypotension;. * Symptoms of coronary artery disease;. * Presence of cardiac arrhythmias on electrocardiograph (EKG) requiring drug therapy;. * Ejection fraction \\< 50 % (echocardiogram or multi gated acquisition scan \\[MUGA\\]). * Symptomatic central nervous system metastases greater than 1 cm at the time of therapy; patients with 1-2 asymptomatic, less than 1 cm brain/central nervous system (CNS) metastases without significant edema may be considered for treatment; if sub-centimeter CNS lesions are noted at study entry, than a repeat imaging will be performed if more than 3 weeks have elapsed from the last scan; patients will not be treated if CNS lesions are \\> 1 cm or if patient is symptomatic from brain metastasis. * Patients with active infections or oral temperature \\> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy. * Chemotherapeutic agents (standard or experimental), radiation therapy, or other immunosuppressive therapies less than 3 weeks prior to T cell therapy; (patients with bulky disease may undergo cytoreductive chemotherapy but treatment will be discontinued at least 3 weeks prior to T cell therapy). * Clinically significant autoimmune disorders or conditions of immunosuppression; patients with acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to HIV antibody seropositive or known to be recently polymerase chain reaction (PCR)+ for hepatitis are not eligible for this study; virology testing will be done within 6 months of T cell infusion; the severely depressed immune system found in these infected patients and the possibility of premature death would compromise study objectives. * FOR T CELL INFUSION: Patients with active infections or oral temperature \\> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy. * FOR T CELL INFUSION: Chemotherapeutic agents (standard or experimental), radiation therapy, or other immunosuppressive therapies less than 3 weeks prior to T cell therapy. * FOR T CELL INFUSION: Current treatment with steroids. * FOR T CELL INFUSION: Patients must not be receiving any other experimental drugs within 3 weeks of the initiation of the protocol and must have recovered from all side effects of such therapy", "labeled_rules": [{"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "(patients with bulky disease may undergo cytoreductive chemotherapy but treatment will be discontinued at least 3 weeks prior to T cell therapy)"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 50, "unit": "years", "evidence_text": "* Normal cardiac stress test within 182 days prior to enrollment is required of all patients over 50 years old or those with an abnormal electrocardiogram (ECG), any history of cardiac disease, a family history of cardiac disease, hypercholesterolemia or hypertension"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "women of childbearing potential must have a negative pregnancy test within two weeks prior to entry"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "* Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "steroids", "unit": null, "evidence_text": "* FOR T CELL INFUSION: Current treatment with steroids"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the severely depressed immune system found in", "unit": null, "evidence_text": "the severely depressed immune system found in these infected patients and the possibility of premature death would compromise study objectives"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* Patients with active infections or oral temperature \\> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* FOR T CELL INFUSION: Patients with active infections or oral temperature \\> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "patients with acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to HIV antibody seropositive or known to be recently polymerase chain reaction (PCR)+ for hepatitis are not eligible for this study"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the diagnosis of metastatic disease", "unit": null, "evidence_text": "* Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "cardiac disease, a family history of cardiac", "unit": null, "evidence_text": "* Normal cardiac stress test within 182 days prior to enrollment is required of all patients over 50 years old or those with an abnormal electrocardiogram (ECG), any history of cardiac disease, a family history of cardiac disease, hypercholesterolemia or hypertension"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "women of childbearing potential must have a negative pregnancy test within two weeks prior to entry"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence"}]}
{"nct_id": "NCT00440817", "eligibility_text": "Inclusion Criteria:. * Patients with Crohns disease or rheumatoid arthritis who participate in the specified registries will be included in the analysis. For the lymphoma analysis, patients must be recorded as having a lymphoma during their participation in one of these registries. Exclusion Criteria:. * Patients who do not have Crohns disease or rheumatoid arthritis and who did not participate in one of the identified registries will be excluded from the study", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "for the lymphoma analysis", "unit": null, "evidence_text": "For the lymphoma analysis, patients must be recorded as having a lymphoma during their participation in one of these registries"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* Patients with Crohns disease or rheumatoid arthritis who participate in the specified registries will be included in the analysis"}]}
{"nct_id": "NCT00454805", "eligibility_text": "Inclusion Criteria:. * Written informed consent. * Females with histological/cytological confirmation of hormone sensitive breast cancer with evidence of metastatic disease. * One or more evaluable lesions. Exclusion Criteria:. * Prior hormonal therapy with fulvestrant. * More than one course of prior systemic cytotoxic chemotherapy for metastatic breast cancer. * Prior biologic therapy for ABC including Anti-VEGF agents. * Radiation therapy within 4 weeks prior to provision of consent", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "fulvestrant", "unit": null, "evidence_text": "* Prior hormonal therapy with fulvestrant"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "evidence of metastatic disease", "unit": null, "evidence_text": "* Females with histological/cytological confirmation of hormone sensitive breast cancer with evidence of metastatic disease"}]}
{"nct_id": "NCT00457600", "eligibility_text": "Inclusion Criteria:. * Age less than 12 years with head trauma. * Age less than 12 years with ear pain. * Ages less than 12 years with concern for UTI. * 1 year - 12 years with asthma history and respiratory chief complaint. * 3 months - 2 years with fever. * Parent speaks English or Spanish. * Triage status is non-emergent", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fever", "unit": null, "evidence_text": "* 3 months - 2 years with fever"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "ear pain", "unit": null, "evidence_text": "* Age less than 12 years with ear pain"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "head trauma", "unit": null, "evidence_text": "* Age less than 12 years with head trauma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "concern for uti", "unit": null, "evidence_text": "* Ages less than 12 years with concern for UTI"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "asthma history and respiratory chief complaint", "unit": null, "evidence_text": "* 1 year - 12 years with asthma history and respiratory chief complaint"}]}
{"nct_id": "NCT00468039", "eligibility_text": "Inclusion Criteria:. * Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes. * Diagnosis of type 2 diabetes for at least 4 weeks prior to study entry. * Body mass index 22-40 kg/meter squared. * HbA1c \\> 11% and/or FPG \\>270 mg/dL. Exclusion Criteria:. * Pregnant or lactating female. * History of type 1 diabetes. * Evidence of significant diabetic complications. * Treatment with insulin or any other oral antidiabetic agent. Other protocol-defined inclusion/exclusion criteria may apply.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 4, "unit": "years", "evidence_text": "* Diagnosis of type 2 diabetes for at least 4 weeks prior to study entry"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or lactating female"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "type 1 diabetes", "unit": null, "evidence_text": "* History of type 1 diabetes"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "insulin or any other oral antidiabetic agent", "unit": null, "evidence_text": "* Treatment with insulin or any other oral antidiabetic agent"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "type 2 diabetes for at least 4", "unit": null, "evidence_text": "* Diagnosis of type 2 diabetes for at least 4 weeks prior to study entry"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "type 2 diabetes", "unit": null, "evidence_text": "* Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Pregnant or lactating female"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "breastfeeding", "unit": null, "evidence_text": "* Pregnant or lactating female"}]}
{"nct_id": "NCT00483301", "eligibility_text": "Inclusion Criteria:. * Histologically confirmed diagnosis of melanoma with measurable disease. * Patients with stage IV, previously untreated, refractory to initial therapy or progressing after response to initial therapy. * Patients with unresectable stage III, including unresectable in-transit metastases. * Two prior chemotherapy regimen is allowed. * One prior immunotherapy regimen is allowed. * No other concurrent investigational therapy. * Radiation therapy to non-target lesions or to one of multiple target lesions may be allowed on a case-by-case basis. * Patients must be past the nadir from previous cytotoxic therapy. * Age at least 18 years. * ECOG performance status 0-2. * Hemoglobin \\> 9.0 g/dl, absolute neutrophil count (ANC) \\> 1,500/mm3, platelet count \\> 100,000/mm3. * Total bilirubin within normal limits, ALT and AST \\< 2.0 x the ULN ( \\< 5 x ULN for patients with liver involvement), INR \\< 1.5 and aPTT within normal limits. Patients who receive anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre dose, as defined by the local standard of care.. * Creatinine \\< 1.5 x ULN, serum calcium within normal limits. * Patients with stable brain metastasis who have been treated with either whole brain radiation or Gamma Knife and have been off steroids for \\> 4 weeks. * Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men and women should use adequate birth control for at least three months after the last administration of protocol drugs. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.. * Ability to understand and sign a written informed consent document. All patients must have a signed informed consent before registration and initiation of therapy. Exclusion Criteria:. * Cardiac disease: Congestive heart failure \\> class II NYHA.. * Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.. * Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.. * Uncontrolled hypertension defined as systolic blood pressure \\> 150 mmHg or diastolic pressure \\> 90 mmHg, despite optimal medical management.. * No known severe hypersensitivity or suspected allergy to sorafenib, ABI-007 or any of the excipients. * Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude progressing brain metastasis.. * Peripheral neuropathy greater than grade II. * Serious intercurrent medical or psychiatric illness, including serious active infection. * Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.. * Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.. * Pulmonary hemorrhage/bleeding event \\> CTCAE Grade 2 within 4 weeks of first dose of study drug.. * Any other hemorrhage/bleeding event \\> CTCAE Grade 3 within 4 weeks of first dose of study drug.. * Serious non-healing wound, ulcer, or bone fracture.. * Evidence or history of bleeding diathesis or coagulopathy. * Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.. * Use of St. John's Wort or rifampin (rifampicin). * Any condition that impairs patient's ability to swallow whole pills.. * Any malabsorption problem. * No treatment for melanoma within the previous 4 weeks.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Age at least 18 years"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Men and women should use adequate birth control for at least three months after the last administration of protocol drugs"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Men and women should use adequate birth control for at least three months after the last administration of protocol drugs"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "* Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "bleeding diathesis or coagulopathy", "unit": null, "evidence_text": "* Evidence or history of bleeding diathesis or coagulopathy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "* Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* Serious intercurrent medical or psychiatric illness, including serious active infection"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "melanoma with measurable disease", "unit": null, "evidence_text": "* Histologically confirmed diagnosis of melanoma with measurable disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "unresectable stage iii, including unresectable in-transit metastases", "unit": null, "evidence_text": "* Patients with unresectable stage III, including unresectable in-transit metastases"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "an agent such as warfarin or heparin", "unit": null, "evidence_text": "Patients who receive anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "x uln for", "unit": null, "evidence_text": "* Total bilirubin within normal limits, ALT and AST \\< 2.0 x the ULN ( \\< 5 x ULN for patients with liver involvement), INR \\< 1.5 and aPTT within normal limits"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "* Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months"}]}
{"nct_id": "NCT00502853", "eligibility_text": "Inclusion Criteria:. * adult patients, 18-75 years of age;. * rheumatoid arthritis for \\>=3 months and \\<=10 years;. * inadequate response to methotrexate (12.5-25mg/week) for \\>=3 months;. * evidence of erosive disease and/or clinical synovitis in a signal joint.. Exclusion Criteria:. * autoimmune rheumatic diseases other than RA;. * surgical operations on bones/joints in 12 weeks prior to baseline visit;. * concomitant treatment with biologic agents;. * previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* adult patients, 18-75 years of age"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "* adult patients, 18-75 years of age"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "biologic agents", "unit": null, "evidence_text": "* concomitant treatment with biologic agents"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "more than one biologic agent approved for", "unit": null, "evidence_text": "* previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "adult", "unit": null, "evidence_text": "* adult patients, 18-75 years of age"}]}
{"nct_id": "NCT00510302", "eligibility_text": "Inclusion Criteria:. * (FDRs will include siblings and adult children.) Melanoma patients are eligible if they were diagnosed with in situ, localized, or regional melanoma after January 1, 1997.. * Melanoma patients, their spouses/partners, and their first-degree relatives (FDRs) 18 years of age or older are eligible.. * Melanoma patients, their spouses/partners, and FDRs are eligible if they can speak, read, and write English.. * Melanoma patients, their spouses/partners, and FDRs are eligible if they provide informed consent.. * Spouses/partners and FDRs of melanoma patients are eligible if the patient gives permission for them to be contacted for recruitment.. * A melanoma patient's FDR is eligible if he/she is a sibling or child of the melanoma patient.. Exclusion Criteria:. * Melanoma patients, spouses/partners of patients, and FDRs of patients are not eligible if they cannot provide informed consent.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "melanoma", "unit": null, "evidence_text": "* Melanoma patients, spouses/partners of patients, and FDRs of patients are not eligible if they cannot provide informed consent"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "melanoma", "unit": null, "evidence_text": "* Melanoma patients, their spouses/partners, and FDRs are eligible if they provide informed consent"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "melanoma", "unit": null, "evidence_text": "* Melanoma patients, their spouses/partners, and FDRs are eligible if they can speak, read, and write English"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "melanoma", "unit": null, "evidence_text": "* Melanoma patients, their spouses/partners, and their first-degree relatives (FDRs) 18 years of age or older are eligible"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "partners and fdrs of melanoma", "unit": null, "evidence_text": "* Spouses/partners and FDRs of melanoma patients are eligible if the patient gives permission for them to be contacted for recruitment"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "in situ, localized, or regional melanoma after", "unit": null, "evidence_text": "* (FDRs will include siblings and adult children.) Melanoma patients are eligible if they were diagnosed with in situ, localized, or regional melanoma after January 1, 1997"}]}
{"nct_id": "NCT00516776", "eligibility_text": "Inclusion Criteria:. * Presence of ulcerative colitis. * Presence of Crohn's disease. * Healthy (no sign of inflammatory bowel disease). Exclusion Criteria:. * Anticoagulation. * Cardiac valvular disease. * Intravascular prosthesis. * Coagulation disorders. * Gastrointestinal malignancy", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* Presence of ulcerative colitis"}]}
{"nct_id": "NCT00548574", "eligibility_text": "Inclusion Criteria:. * newly diagnosed or relapsing mild to moderate UC (score of 4-10 (inclusive) on the UC-DAI scale, with a sigmoidoscopy score of =\\> 1 and a PGA \\<=2) with compatible histology. * females eligible if post--menopausal, surgically sterile or if they had a negative urine pregnancy test at screening and were on adequate contraception. Exclusion Criteria:. * subjects with relapsing UC who were in relapse for \\> 6 weeks prior to baseline. * subjects who relapsed on maintenace therapy with doses of mesalazine =\\> 2g/day. * subjects who had unsuccessfully treated their current relapse with steroids or a mesalazine dose of \\> 2g/day. * subjects with Crohn's disease, proctitis, bleeding disorders, active peptic ulcer disease, previous colonic surgery, or those at an immediate risk of toxic megacolon or a stool culture positive for enteric pathogens. * subjects who had used systemic or rectal steroids within the last 4 weeks, immunosuppressants wihtin the last 6 weeks or anti-inflammatory drugs on a repeat basis within 7 days prior to the baseline visit. * subjects with hypersensitivity to salicylates and subjects with moderate/severe renal impairment", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "compatible histology", "unit": null, "evidence_text": "* newly diagnosed or relapsing mild to moderate UC (score of 4-10 (inclusive) on the UC-DAI scale, with a sigmoidoscopy score of =\\> 1 and a PGA \\<=2) with compatible histology"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "* subjects who had used systemic or rectal steroids within the last 4 weeks, immunosuppressants wihtin the last 6 weeks or anti-inflammatory drugs on a repeat basis within 7 days prior to the baseline visit"}]}
{"nct_id": "NCT00550758", "eligibility_text": "Inclusion Criteria:. * age 3- to 6-years. * respiratory diseases who were highly indicative of asthma diagnosis according to GINA guidelines \\[9\\]. * cough duration of more than 4 weeks. * normal chest auscultation and baseline FEV1\\>75% predicted for healthy preschool children, on the day of testing.. Exclusion Criteria:. * presence of other chronic respiratory conditions. * emergency room visit or the presence of respiratory infection within the last month. * oral or inhaled steroids or other anti-inflammatory medication taken in the last two weeks. * bronchodilator taken within 24-hours prior to the test.", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* age 3- to 6-years"}]}
{"nct_id": "NCT00576069", "eligibility_text": "Inclusion Criteria:. * Current non-smoking (\\<10 pack yr smoking history). * Stable, treated asthmatics. * Age 12-95 yr. * post 180ug albuterol by MDI: FEV 1/FVC \\< 70% and FEV 1 \\<80% predicted. Exclusion Criteria:. * Pregnancy", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 12, "unit": "years", "evidence_text": "* Age 12-95 yr"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 95, "unit": "years", "evidence_text": "* Age 12-95 yr"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Pregnancy"}]}
{"nct_id": "NCT00584350", "eligibility_text": "Inclusion Criteria:. * minimum 18 years old. * chronic renal insufficiency with a calculated creatinine clearance below 60 cc /min. (estimated with the MDRD formula). * hemodynamically stable. Exclusion Criteria:. * Acute renal failure or in recuperation of acute renal failure. * urgent coronary angiogram. * moderate to severe valvulopathy or presence of a valvular prosthesis. * diagnostic of multiple myeloma. * dialysis before test. * having had a test with contrast product in the 2 weeks preceding. * receiving a nephrotoxic in the last month.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "contrast product in the 2 weeks preceding", "unit": null, "evidence_text": "* having had a test with contrast product in the 2 weeks preceding"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* minimum 18 years old"}]}
{"nct_id": "NCT00595361", "eligibility_text": "Inclusion Criteria:. * Both male and female. * 18 to 50 years of age. * Resting FEV1 ≥ 65% of predicted normal. * Exercise-induced bronchoconstriction defined as a decrease in FEV1 of ≥ 20% following a standardized exercise challenge when compared to pre-exercise baseline FEV1 value measured 5 minutes before exercise. * Must be Arg/Arg or Gly/Gly genotype. Exclusion Criteria:. * Long-acting beta agonist use within 12 weeks of the first exercise challenge. * Smoking within past 12 months. * Greater than 10-pack years smoking history. * Unresolved signs and/or symptoms of an upper respiratory tract infection within 4 weeks of first exercise challenge. * Asthma exacerbation within 4 weeks of first exercise challenge requiring change in type, dose or frequency of medications and/or an unscheduled visit to an health care provider, including emergency room or hospital. * Subject has exercised or performed strenuous activity within 72 hours of the first exercise challenge. * Subject has been exposed to cold air sufficient to provoke symptoms of bronchospasm within 2 hours of exercise challenge. * In addition to asthma, the subject has an active, acute or chronic pulmonary disorder documented by history, physical examination, or chest x-ray. * Subject has evidence of ischemic, valvular, hypertrophic, familial or other forms of heart disease that would put the subject at risk during exercise testing or that would interfere with the ability to achieve protocol-specified heart rates during exercise testing. * Subject has used systemic corticosteroids within 1 month of first exercise challenge", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* 18 to 50 years of age"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 50, "unit": "years", "evidence_text": "* 18 to 50 years of age"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Both male and female"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the ability to achieve protocol-specified heart rates", "unit": null, "evidence_text": "* Subject has evidence of ischemic, valvular, hypertrophic, familial or other forms of heart disease that would put the subject at risk during exercise testing or that would interfere with the ability to achieve protocol-specified heart rates during exercise testing"}]}
{"nct_id": "NCT00628095", "eligibility_text": "Inclusion Criteria:. * Active rheumatoid arthritis. * Incomplete response to methotrexate. Exclusion Criteria:. * Must not be on biologic therapies. * No recent infections", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* Active rheumatoid arthritis"}]}
{"nct_id": "NCT00642564", "eligibility_text": "Inclusion Criteria:. * Patients diagnosed with epilepsy. * Patients or parent(s)/caregiver(s) have signed and dated an informed consent.. Exclusion Criteria:. * Patients who have non-epileptic events in addition to epilepsy, such as pseudoseizures or an acute symptomatic cause of seizures (e.g., a metabolic disturbance, toxic exposure, active CNS infection). * Patients with progressive or degenerative neurological disorder. * Patients with an active malignancy. * Patients or parents/caregivers with known or suspected psychotic disease, mental retardation, or any mental situation which may cause the concern to properly complete this survey.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "an active malignancy", "unit": null, "evidence_text": "* Patients with an active malignancy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "progressive or degenerative neurological disorder", "unit": null, "evidence_text": "* Patients with progressive or degenerative neurological disorder"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "epilepsy", "unit": null, "evidence_text": "* Patients diagnosed with epilepsy"}]}
{"nct_id": "NCT00649922", "eligibility_text": "Inclusion Criteria:. * Male/Females at least 20 years of age.. * Females post-menopausal for at least 1 year, surgically sterile, or practicing acceptable methods of birth control.. * Females have a negative pregnancy test at screening.. * Diagnosis of RA and met ACR criteria.. * Must discontinue any TNF at least 2 months prior to baseline.. * In condition of general good health.. Exclusion Criteria:. * History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix.. * History of current acute inflammatory joint disease.. * Use of TAMIFLU or Symmetrel within 3 months of study drug administration.. * Recent (3 month) history of influenza or pneumococcal bacterial infection.. * Known positive human immunodeficiency virus (HIV) status.. * Positive hepatitis B or hepatitis C virus.. * Positive PPD \\>5 mm.. * Chest x-ray with calcified granulomas and/or pleural scarring or significant abnormalities.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 20, "unit": "years", "evidence_text": "* Male/Females at least 20 years of age"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 2, "unit": "years", "evidence_text": "* Must discontinue any TNF at least 2 months prior to baseline"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* Females post-menopausal for at least 1 year, surgically sterile, or practicing acceptable methods of birth control"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "active infection with Listeria or TB"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "listeria or tb", "unit": null, "evidence_text": "active infection with Listeria or TB"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "significant sensitivity to any drug", "unit": null, "evidence_text": "* History of significant sensitivity to any drug"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "current acute inflammatory joint disease", "unit": null, "evidence_text": "* History of current acute inflammatory joint disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "* Known positive human immunodeficiency virus (HIV) status"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "influenza or pneumococcal bacterial infection", "unit": null, "evidence_text": "* Recent (3 month) history of influenza or pneumococcal bacterial infection"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "ra and met acr", "unit": null, "evidence_text": "* Diagnosis of RA and met ACR criteria"}]}
{"nct_id": "NCT00685425", "eligibility_text": "Inclusion Criteria:. * Subject, male or female, must be at least 12 years of age at the time of consent.. * Female subjects 12-60 years of age must have a negative serum pregnancy test.. * Women of child bearing potential must be using an acceptable method of birth control throughout the study.. * Subject must have a documented diagnosis of asthma for a minimum of 6 months prior to study start. * Subject must be in good health with the exception of their reversible airways disease and not suffering from any chronic condition that might affect their respiratory function.. * Subject must have a chest X-ray for the study or within 12 months prior to randomization.. * Subject must be able to complete the diary cards and medical event calendars reliably on a daily basis and understand dosing instructions. Any minor subject who is not able to do this must have a parent/legal guardian who can assist them during the study with these activities.. Exclusion Criteria:. * Female subject who is pregnant or lactating.. * Subject who has participated in an investigational drug study within 30 days of study start, or who is currently participating in another clinical trial.. * Subject whose schedule prevents him or her from starting study visits before 12 PM.. * Subject who is unwilling or physically unable to perform the exercise challenges as described in the protocol.. * Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both.. * Subject who has a history of hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial.. * Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations.. * Subject using any prescription drug with which albuterol sulfate administration is contraindicated.. * Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start.. * Subject with a history of cancer (exception: basal cell carcinoma in remission).. * Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication or that may interfere with the successful completion of this protocol.. * Subject with a history of substance abuse or drug abuse within 12 months preceding study start. Urine drug test must be negative at study start.. * Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start.. * Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis.. * Subject who has suffered from a clinically significant upper or lower respiratory tract infection in the 3 weeks prior to study start.. * Subjects with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks.. * Subject who is a staff member or relative of a staff member.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 12, "unit": "years", "evidence_text": "* Female subjects 12-60 years of age must have a negative serum pregnancy test"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 60, "unit": "years", "evidence_text": "* Female subjects 12-60 years of age must have a negative serum pregnancy test"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 12, "unit": "years", "evidence_text": "* Subject, male or female, must be at least 12 years of age at the time of consent"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 6, "unit": "years", "evidence_text": "* Subject must have a documented diagnosis of asthma for a minimum of 6 months prior to study start"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female subject who is pregnant or lactating"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female subjects 12-60 years of age must have a negative serum pregnancy test"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Subject, male or female, must be at least 12 years of age at the time of consent"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women of child bearing potential must be using an acceptable method of birth control throughout the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "unstable asthma", "unit": null, "evidence_text": "* Subjects with unstable asthma"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a history of substance abuse or drug", "unit": null, "evidence_text": "* Subject with a history of substance abuse or drug abuse within 12 months preceding study start"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "which albuterol sulfate administration is contraindicated", "unit": null, "evidence_text": "* Subject using any prescription drug with which albuterol sulfate administration is contraindicated"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a documented history of bronchopulmonary aspergillosis or", "unit": null, "evidence_text": "* Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "measurements or compliance or both", "unit": null, "evidence_text": "* Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cigarette smoking or use of any tobacco", "unit": null, "evidence_text": "* Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the successful completion of this protocol", "unit": null, "evidence_text": "* Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication or that may interfere with the successful completion of this protocol"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypercapnia, respiratory arrest, or hypoxic seizures within", "unit": null, "evidence_text": "* Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start"}]}
{"nct_id": "NCT00687440", "eligibility_text": "Inclusion Criteria:. Patients must fulfill all the following criteria:. * Females aged 18 to 70 years-old.. * Willingness to participate in the study and comply with its procedures.. * Documented diagnosis of metastatic breast carcinoma (stage IV) Human Epidermal Growth Factor Receptor 2 (HER2) overexpressing (Immunohistochemistry (IHC) 3+ or Fluorescence In Situ Hybridization(FISH) +).. * No prior chemotherapy for metastatic breast cancer.. * Adjuvant or neo-adjuvant chemotherapy is allowed according to the following rules:. * patients treated with anthracyclines if all the following conditions are met:. * Doxorubicin total dose \\<= 300 mg/m\\^2. * Epirubicin total dose \\<= 480 mg/m\\^2. * Chemotherapy-free interval of \\> 12 months. * no taxane-based adjuvant or neo-adjuvant chemotherapy is allowed;. * patients treated with non-anthracycline/taxane adjuvant or neo-adjuvant chemotherapy regimens are freely eligible (i.e. cyclophosphamide/methotrexate/fluorouracil (CMF) or similar regimens).. * At least one measurable lesion according to RECIST criteria.. * Complete hematologic and biologic baseline evaluation within 2 weeks prior to start of treatment.. * Complete Tumor baseline evaluation including a total body computed tomography (CT) scan within 4 weeks prior to start of treatment.. * Left ventricular ejection fraction (LVEF) \\>= 50% as determined by echocardiogram or Multi Gated Acquisition (MUGA) scan.. * World Health Organization (WHO) performance status 0,1.. * Life expectancy \\> 3 months.. * Laboratory requirements :. * Hematology :. * Neutrophils \\> 1.5 x 10\\^9/L. * Platelets \\> 100 x 10\\^9/L. * Hemoglobin \\> 10 g/dL. * Hepatic function:. * Total bilirubin \\<= 1.25 x the upper-normal limits (UNL);. * ASAT (Aspartate Aminotransferase or SGOT), ALAT (Alanine aminotransferase or SGPT) \\<= 2.5 x the upper-normal limits;. * For patients with liver metastases:. * Total bilirubin \\< 1.5 x the UNL (Upper limit of normal) ;. * ASAT and/or ALAT \\< 3 x the UNL;. * Renal function :. * Serum Creatinine \\< 1.5 x the UNL.. * Women of child bearing potential must have a negative serum pregnancy test and be using adequate contraception.. * Patients must be accessible for treatment and follow-up.. Exclusion Criteria:. Patients will not be enrolled if any of the following criteria apply:. * Prior chemotherapy for metastatic disease.. * History of prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ).. * Radiation to disease areas within 3 weeks of study initiation.. * Symptomatic peripheral neuropathy \\> grade 2 according to the National Cancer Institute (NCI) Common Toxicity Criteria.. * Other serious illness or medical condition.. * LVEF \\< 50% as determined by echocardiogram or MUGA scan.. * Congestive hearth failure or angina pectoris even if it is medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia.. * History of significant neurologic or psychiatric disorders including dementia or seizures.. * Active infection.. * Active peptic ulcer, unstable diabetes mellitus or other contraindications for the use of dexamethasone.. * Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening.. * Concurrent treatment with corticosteroids used for reasons other than for premedication. However patients receiving chronic treatment with corticosteroids (\\> 6 months) at low dose (\\< 20 mg of methylprednisolone or equivalent dose of other corticosteroids) for whichever reason are eligible.. * Taxane-based adjuvant or neo-adjuvant chemotherapy \\< 12 months.. * Other concurrent chemotherapy, immunotherapy, radiotherapy or any other investigational medication, for the treatment of the tumor.. * Pregnant or breast-feeding women.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Females aged 18 to 70 years-old"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 70, "unit": "years", "evidence_text": "* Females aged 18 to 70 years-old"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or breast-feeding women"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women of child bearing potential must have a negative serum pregnancy test and be using adequate contraception"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* Active infection"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "other experimental drugs", "unit": null, "evidence_text": "* Concurrent treatment with other experimental drugs"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "corticosteroids used for reasons other than for", "unit": null, "evidence_text": "* Concurrent treatment with corticosteroids used for reasons other than for premedication"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "significant neurologic or psychiatric disorders including dementia", "unit": null, "evidence_text": "* History of significant neurologic or psychiatric disorders including dementia or seizures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any investigational drug within 30 days prior", "unit": null, "evidence_text": "Participation in another clinical trial with any investigational drug within 30 days prior to study screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "however", "unit": null, "evidence_text": "However patients receiving chronic treatment with corticosteroids (\\> 6 months) at low dose (\\< 20 mg of methylprednisolone or equivalent dose of other corticosteroids) for whichever reason are eligible"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "its procedures", "unit": null, "evidence_text": "* Willingness to participate in the study and comply with its procedures"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Pregnant or breast-feeding women"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 10, "unit": "years", "evidence_text": "* History of prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ)"}]}
{"nct_id": "NCT00697580", "eligibility_text": "Inclusion Criteria:. * Overweight (age- \\& sex-specific body mass index ≥ 85th percentile based on CDC BMI growth charts \\[US Department of Health and Human Services, 2000\\], calculated by Epi Info Software, version 3.3). * Latino (both sets of grandparents must be of Latino heritage as defined by self-report; limited to Latinos to maintain a homogeneous sample and because Latinos are at increased risk of insulin resistance and type 2 diabetes.) If the participant or the parent is unsure of the country of origin of all 4 grandparents they will be excluded from the study. The participants and their families are not asked whether or not their grandparents are undocumented immigrants.. Exclusion Criteria:. * Presently taking medication(s) or diagnosed with any syndrome or disease that could influence dietary intake, exercise ability, body composition and fat distribution, or insulin action and secretion.. * Previously diagnosed with any major illness since birth (e.g. severe intrauterine growth retardation, chronic birth asphyxia, cancer).. * Children will not be eligible for participation if they have any diagnostic criteria for diabetes including polyuria, polydipsia with or without unexplained weight loss, fasting plasma glucose \\> 126 mg/dl, or a 2-hour plasma glucose \\>200 mg/dL during an oral glucose tolerance test. Children will also be excluded if they test positive for diabetes-related auto-antibodies, including ICA512 and GAD. Children testing positive for type 2 diabetes will be referred for treatment. Children with impaired glucose tolerance (fasting glucose \\>110 mg/dL or 2-hour glucose \\>140 mg/dl during an OGTT) and/or conditions associated with insulin resistance (e.g. acanthosis nigricans, hypertension, dyslipidemia, PCOS) will be eligible, as long as they are not receiving treatment and meet other eligibility criteria.. * Participants who are involved in any weight training, exercise, nutrition, or weight loss program or have been in the past 6 months.. * Participants that do not follow the rules and guidelines of appropriate conduct during participation, i.e., disruptive behavior, derogatory or racist comments, or any acts of physical violence towards study staff or other participants, and use of illegal substances. The principal investigator Dr. Michael Goran will decide if this conduct warrants exclusion or removal from the study.. * Pregnancy test comes out positive.. * Children who live further than 20 miles away from the General Clinic Research Center (GCRC).. * We can terminate participation if the child fails to follow the rules and guidelines of appropriate behavior and conduct during participation.", "labeled_rules": [{"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Pregnancy test comes out positive"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* Overweight (age- \\& sex-specific body mass index ≥ 85th percentile based on CDC BMI growth charts \\[US Department of Health and Human Services, 2000\\], calculated by Epi Info Software, version 3.3)"}]}
{"nct_id": "NCT00702325", "eligibility_text": "Inclusion Criteria:. * African American (self-reported). * Documented clinical diagnosis of asthma as defined by the American Thoracic Society (ATS) for at least 6 months prior to Visit 2 and be in stable condition.. * FEV1, measured ≥6 hours after the last dose of short-acting β2-agonist and at least 48 hours after LABA, of 45%-85%, inclusive, of predicted normal.. Exclusion Criteria:. * Has been hospitalized at least once for an asthma related condition during the 6 months prior to Visit 2, or has required emergency treatment due to an asthma related condition more than once in the 3 months prior to Visit 2.. * Has required treatment with systemic corticosteroids (eg, oral, parenteral, ocular, or rectal) for any reason within the 30 days prior to Visit 2.. * Has a respiratory infection or other viral/bacterial illness, or is recovering from such an illness at the time of Visit 3 that, in the Investigator's opinion, will interfere with the subject's lung function and/or ability to perform spirometry", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 48, "unit": "years", "evidence_text": "* FEV1, measured ≥6 hours after the last dose of short-acting β2-agonist and at least 48 hours after LABA, of 45%-85%, inclusive, of predicted normal"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 6, "unit": "years", "evidence_text": "* Documented clinical diagnosis of asthma as defined by the American Thoracic Society (ATS) for at least 6 months prior to Visit 2 and be in stable condition"}]}
{"nct_id": "NCT00702611", "eligibility_text": "Inclusion Criteria:. * 18 - 75 years old. * Active ulcerative colitis with documented clinical symptoms and endoscopic findings. * Active disease defined as DAI (Mayo score) ≥ 4 and ≤10 with at least 1 point in flexible sigmoidoscopy. * Steroid dependency as defined by:. A. Inability to withdraw corticosteroids within three months of starting treatment, without recurrent active disease. B. appearance of relapse within 3 months after withdrawal of corticosteroids. * Colonic involvement with ulcerative colitis beyond 15cm of the anal verge. * Stable doses:A. Aminosalicylates for the last 4 weeks B. Prednisolone or equivalent dose ≤ 20 mg/day for the last 2 weeks C. Azathioprine or 6-mercaptopurine at stable dose for the last 12 weeks. * Signed informed consent form. * Agree to participate in the required follow-up visits. * Able to complete the diary. Exclusion Criteria:. * Febrile (\\> 38ºC). * Evidence of toxic megacolon. * Anticipated need for surgery within 24 weeks. * Known obstructive diseases of the gastrointestinal system. * Proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis. * A history of allergic reaction to heparin or heparin-induced thrombocytopenia. * A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures. * Requires a central venous access catheter for the apheresis treatments. * Known infection with enteric pathogens, pathogenic ova or parasites, C. difficile toxin or CMV. * Hypotension (systolic blood pressure \\<80 mmHg and/or diastolic blood pressure \\<50 mmHg) at screening visit only. * Uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>120 mmHg) despite medical therapy. * A history of myocardial infarction or unstable angina within the past 6 months. * A history of coronary artery bypass grafting surgery or angioplasty within the past 6 months. * Prosthetic heart valve, pacemaker or other permanent implant. * Severe cardiovascular or peripheral vascular disease, severe renal disease. * Liver disease defined as levels of SGOT \\[AST\\], SGPT \\[ALT\\] or alkaline phosphatase \\>2.5x the upper limit of the normal range for the laboratory performing test. * History of cirrhosis. * Known bleeding disorder (PT or PTT\\>1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for purposes other than apheresis treatment. * Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis. * Known infection with Hepatitis B or C, or HIV. * Abnormal hematology parameters defined as severe anemia with hemoglobin \\<8.5g/dL, white blood cell count of \\<3,500/μl and a granulocyte count \\< 2,000/μl. * Fibrinogen level \\>700mg/dL. * Major surgery within the past 6 months. * Infection:Active infections less than 4 weeks from successful completion of antibiotic treatment for routine bacterial infectionFebrile viral infection within 4 weeks of entry into the clinical investigationLess than 12 weeks from conclusion of therapy for systemic fungal infections. * Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II). * History of dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding UC (\\> 10 años). * Current drug or alcohol abuse. * Pregnant, lactating or planning to become pregnant during the course of the clinical investigation. * Used within the last 30 days an investigational drug, biologic or device or 5 half-lifes, if known, for any investigational drug or biologic. * Received cyclosporine or tacrolimus within the last 8 weeks. * Received infliximab within the last 8 weeks. * Fulminant ulcerative colitis", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* 18 - 75 years old"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "* 18 - 75 years old"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* Active disease defined as DAI (Mayo score) ≥ 4 and ≤10 with at least 1 point in flexible sigmoidoscopy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cirrhosis", "unit": null, "evidence_text": "* History of cirrhosis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "* Known infection with Hepatitis B or C, or HIV"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hepatitis b or c, or hiv", "unit": null, "evidence_text": "* Known infection with Hepatitis B or C, or HIV"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "enteric pathogens, pathogenic ova or parasites, c", "unit": null, "evidence_text": "* Known infection with enteric pathogens, pathogenic ova or parasites, C"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergic reaction to heparin or heparin-induced thrombocytopenia", "unit": null, "evidence_text": "* A history of allergic reaction to heparin or heparin-induced thrombocytopenia"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "myocardial infarction or unstable angina within the", "unit": null, "evidence_text": "* A history of myocardial infarction or unstable angina within the past 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "coronary artery bypass grafting surgery or angioplasty", "unit": null, "evidence_text": "* A history of coronary artery bypass grafting surgery or angioplasty within the past 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "an apheresis procedure or intolerance of apheresis", "unit": null, "evidence_text": "* A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or carcinoma of the colon or lack", "unit": null, "evidence_text": "* History of dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding UC (\\> 10 años)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* Infection:Active infections less than 4 weeks from successful completion of antibiotic treatment for routine bacterial infectionFebrile viral infection within 4 weeks of entry into the clinical investigationLess than 12 weeks from conclusion of therapy for systemic fungal infections"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "ulcerative colitis beyond 15cm of the anal", "unit": null, "evidence_text": "* Colonic involvement with ulcerative colitis beyond 15cm of the anal verge"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "documented clinical symptoms and endoscopic findings", "unit": null, "evidence_text": "* Active ulcerative colitis with documented clinical symptoms and endoscopic findings"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "at least 1 point in flexible sigmoidoscopy", "unit": null, "evidence_text": "* Active disease defined as DAI (Mayo score) ≥ 4 and ≤10 with at least 1 point in flexible sigmoidoscopy"}]}
{"nct_id": "NCT00710255", "eligibility_text": "Inclusion Criteria:. * Physician diagnosed asthma. * Age 12-75 yrs. * FEV1 \\> 70% predicted. * HIB response \\> 10 %. * No smoking last 6 mo and \\< 10 pack yrs. * No URI last 4 weeks. * No asthma exacerbation last 4 weks. * Able to withhold SABA \\> 8 hrs and LABA \\> 24 hrs. Exclusion Criteria:. * Other lung disease. * Cardiac disease or other condition that would preclude safe participation, on theophylline or leukotriene modifiers", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 12, "unit": "years", "evidence_text": "* Age 12-75 yrs"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "* Age 12-75 yrs"}]}
{"nct_id": "NCT00719134", "eligibility_text": "Inclusion Criteria:. * Patients will be considered for this study if they suffer from classical or common migraine for at least 3 years.. * Candidates will recruited from the clinical case load of Dr. Zahid Bajwa and the headache and pain management center at BIDMC.. * Only patients older than 18 years of age,. * Able to communicate clearly in English,. * Able to give an informed consent will be considered as candidates.. * No limitation of gender or race is justified and thus, it is open to all patients fulfilling criteria for migraine type headache.. * Patients will be able to withdraw from the study at any time.. * They will be included in the study if they meet the criteria for migraine with or without aura (Headache-classification-committee-of-the-International-Headache-Society 1988), if they had \\>4 migraine attacks each month for the previous year.. Exclusion Criteria:. * Exclusion criteria will include cardiovascular or cerebrovascular disorders,. * Cardiac risk factors and liver disease,. * Uncontrolled hypertension,. * Peripheral and central nervous system disorders that affect sensory functions (such as sensory neuropathies and chronic pain),. * The use of opiates or other analgesic drugs for any reason, and the use of other prophylactic anti-migraine drugs.. * Any patient with active hepatitis or elevated liver enzymes (based on their BIDMC medical record) will be excluded as well.. * Employees who are under the direct supervision of the investigators will not participate in the study.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Only patients older than 18 years of age,"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "* Patients will be considered for this study if they suffer from classical or common migraine for at least 3 years"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "only", "unit": null, "evidence_text": "* Only patients older than 18 years of age,"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "no limitation of gender or race is", "unit": null, "evidence_text": "* No limitation of gender or race is justified and thus, it is open to all patients fulfilling criteria for migraine type headache"}]}
{"nct_id": "NCT00721318", "eligibility_text": "2000 RA patients from the East Tallinn Central Hospital's and the North Estonian Regional Hospital's in- and outpatients who live in Tallinn or Harju County. The control sample will be found from the Population Register through matching by gender, age (the same year) and place of residence (living in the city or in the countryside) with the subjects from RA sample according to the official procedure. If required, the research subjects from the control sample will be contacted by a rheumatologist participating in the study.. \\-", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the from ra sample according to the", "unit": null, "evidence_text": "The control sample will be found from the Population Register through matching by gender, age (the same year) and place of residence (living in the city or in the countryside) with the subjects from RA sample according to the official procedure"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "The control sample will be found from the Population Register through matching by gender, age (the same year) and place of residence (living in the city or in the countryside) with the subjects from RA sample according to the official procedure"}]}
{"nct_id": "NCT00724841", "eligibility_text": "Inclusion Criteria:. * Histologically or cytologically confirmed metastatic melanoma. * Up to 1 prior chemotherapy regimen allowed; prior immunotherapy allowed. * Normal organ and marrow function. * Willing to submit to blood sampling for planned PK/PD analyses. * Ability of understand and willingness to sign a written informed consent. Exclusion Criteria:. * No other investigational or commercial agents or therapies. * Prior exposure to GMX1777, GMX1778 or CHS828. * Patients with uncontrolled, intercurrent illness. * Pregnant or breastfeeding women", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": "<=", "value": 1, "unit": "years", "evidence_text": "* Up to 1 prior chemotherapy regimen allowed"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or breastfeeding women"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "uncontrolled, intercurrent illness", "unit": null, "evidence_text": "* Patients with uncontrolled, intercurrent illness"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Pregnant or breastfeeding women"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "breastfeeding", "unit": null, "evidence_text": "* Pregnant or breastfeeding women"}]}
